ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Risperidone for Treatment of Cocaine Dependence in Outpatients - 12

This study has been completed.

Sponsored by: National Institute on Drug Abuse (NIDA)
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000347
  Purpose

The purpose of this study is to evaluate pharmacological efficacy and clinical safety of risperidone in the treatment of cocaine and amphetamine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Risperidone
Phase II

Drug Information available for:   Risperidone    8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))-    Cocaine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Double-Blind, Placebo Control, Parallel Assignment
Official Title:   Risperidone for Treatment of Cocaine Dependence in Outpatients

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:   0
Study Start Date:   July 1997

  Eligibility
Ages Eligible for Study:   21 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

M/F ages 21-50 . Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000347

Locations
United States, California
Friends Research Institute    
      Los Angeles, California, United States, 90025

Sponsors and Collaborators

Investigators
Principal Investigator:     Walter Ling, M.D.     Friends Research Institute, Inc.    
  More Information


Study ID Numbers:   NIDA-3-0010-12, Y01-3-0010-12
First Received:   September 20, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00000347
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Cocaine-Related Disorders
Dopamine
Mental Disorders
Risperidone
Substance-Related Disorders
Disorders of Environmental Origin
Cocaine
Serotonin

Additional relevant MeSH terms:
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Serotonin Antagonists
Serotonin Agents
Therapeutic Uses
Dopamine Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on October 31, 2008




Links to all studies - primarily for crawlers